Abstract
So far, therapeutics focusing on reducing levels of amyloid beta for treatment of Alzheimer’s disease have not been successful in completing clinical trials to come to market, suggesting the need of a wider perspective and the consideration of novel targets of intervention to slow or halt the progression of this disease. One such target is soluble amyloid beta in oligomeric forms, which have been demonstrated to bind with high affinity to zinc released during synaptic activity. This review considers the interaction of AβO and zinc and the role of zinc in neurotransmission along with possible neurotoxic effects of this interaction. Finally, it also discusses recent experimental data in animal models that have translated into potential treatments for AD based on the modulation of hyperexcitability and zinc homeostasis.
Keywords: Amyloid beta, oligomers, zinc, synapses, Alzheimer’s disease.
Current Pharmaceutical Design
Title:Disruption of Zinc Neuromodulation by Aß Oligomers : Therapeutic Implications
Volume: 20 Issue: 15
Author(s): Emily C. Vogler and Jorge Busciglio
Affiliation:
Keywords: Amyloid beta, oligomers, zinc, synapses, Alzheimer’s disease.
Abstract: So far, therapeutics focusing on reducing levels of amyloid beta for treatment of Alzheimer’s disease have not been successful in completing clinical trials to come to market, suggesting the need of a wider perspective and the consideration of novel targets of intervention to slow or halt the progression of this disease. One such target is soluble amyloid beta in oligomeric forms, which have been demonstrated to bind with high affinity to zinc released during synaptic activity. This review considers the interaction of AβO and zinc and the role of zinc in neurotransmission along with possible neurotoxic effects of this interaction. Finally, it also discusses recent experimental data in animal models that have translated into potential treatments for AD based on the modulation of hyperexcitability and zinc homeostasis.
Export Options
About this article
Cite this article as:
Vogler C. Emily and Busciglio Jorge, Disruption of Zinc Neuromodulation by Aß Oligomers : Therapeutic Implications, Current Pharmaceutical Design 2014; 20 (15) . https://dx.doi.org/10.2174/13816128113199990510
DOI https://dx.doi.org/10.2174/13816128113199990510 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
P2X7 Receptor-Associated Programmed Cell Death in the Pathophysiology of Hemorrhagic Stroke
Current Neuropharmacology HCN Channels Modulators: The Need for Selectivity
Current Topics in Medicinal Chemistry Liposomes as Versatile Platform for Cancer Theranostics: Therapy, Bio-imaging, and Toxicological Aspects
Current Pharmaceutical Design Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Phenytoin Induced Chorea: A Rare Adverse Effect of the Drug
Current Drug Safety Synthesis, Anticonvulsant Evaluation of 2,3,4,5-Tetrahydro-7-alkoxy-1H-2-benzazepin-1-ones
Letters in Drug Design & Discovery Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson’s Disease and Huntington’s Disease: A Review
Current Neuropharmacology Pharmacogenetics of the Human MDR1 Multidrug Transporter
Current Pharmacogenomics Pharmacology and Drug Discovery for T-Type Calcium Channels
CNS & Neurological Disorders - Drug Targets Colloidal Polymeric Nanoparticles and Brain Drug Delivery
Current Drug Delivery Preparation and Characterization of Rivastigmine Loaded Human Serum Albumin (HSA) Nanoparticles
Current Drug Delivery History Repeats Itself: Pharmacodynamic Trends in the Treatment of Anxiety Disorders
Current Pharmaceutical Design Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design Deep Brain Stimulation for Alzheimer’s Disease
Current Alzheimer Research Subdural Pharmacotherapy for the Treatment of Intractable Focal Neocortical Epilepsy
Drug Delivery Letters RhoGEFs in Cell Motility: Novel Links Between Rgnef and Focal Adhesion Kinase
Current Molecular Medicine Computational Methods in Determination of Pharmacophore Models of 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub> and 5-HT<sub>7</sub> Receptors
Mini-Reviews in Medicinal Chemistry Sugars that Glow in the Dark: Fluorescent Tagged Glucose Bioprobes and their Facilitation of the Drug Discovery Process
Current Medicinal Chemistry Transcranial Magnetic Stimulation to Understand the Pathophysiology and Treatment of Substance Use Disorders
Current Drug Abuse Reviews Gastrin-Releasing Peptide Receptor as a Molecular Target for Psychiatric and Neurological Disorders
CNS & Neurological Disorders - Drug Targets